Skip to main content
Clinical Trials/NCT03528265
NCT03528265CompletedNot Applicable

Adapting a Rapid Lateral Flow Burkholderia Pseudomallei Immunoassay in Sarawak, Malaysia

Duke University1 site in 1 country100 target enrollmentStarted: June 21, 2018Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
100
Locations
1
Primary Endpoint
Proportion of true negative

Study Overview

Brief Summary

Towards the goal of reducing melioidosis, this study will help clinicians in Sarawak to diagnose and understand the causes and risk factors for melioidosis. The data will help the clinicians to provide faster test results and better clinical care. The investigator's laboratory efforts will supplement available diagnostics by adding a new, easier-to-use test involving lateral flow immunoassay to rapidly detect Burkholderia pseudomallei, a bacterium causing melioidosis. The study aims to study up to 400 patients with melioidosis-like symptoms who are admitted to Kapit Hospital, Sarawak, Malaysia. No participants will be enrolled from other sites. The study will also examine the demographic, behavioral and occupational risk factors associated with hospital admissions to understand any existing associations between these variables and melioidosis prevalence.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
6 Months to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Admitted to Kapit Hospital
  • Fever more than 3 days and one or more of the following:
  • Enlarged cervical, inguinal or axillary lymph nodes (greater than 3 cm in diameter), painless adenopathy or lymphadenitis or lymph node abscesses
  • One or both sides glands involvement such as tender swelling over medial aspect of the lower eyelid of the lacrimal glands; submandibular glands, parotic glands
  • Bedside scan with splenic or liver hypoechoic lesion (less than 2cm in diameter)
  • Pneumonia not responding to 48 hours of first line antibiotics
  • One or more joint pain with swelling
  • Purplish vesicle or bullae mainly over the lower limbs, may resulting in ulcer after rupture
  • Deep seated abscess or brain abscess or genitourinary abscess or osteomyelitis
  • Severe sepsis patient with or without shock and/or with multiorgan involvement

Exclusion Criteria

  • Have a clear alternative diagnosis other than melioidosis by a trained health care professional at the Kapit Hospital
  • Have already been treated for melioidosis (e.g. received antibiotics before the start of the study)
  • Are younger than 6 months of age

Outcomes

Primary Outcomes

Proportion of true negative

Time Frame: up to 5 weeks

Proportion of true negative of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain

Proportion of true positive

Time Frame: up to 5 weeks

Proportion of true positive of Bukholderia pseudomallei using rapid diagnostic tests compared to the results of qPCR, bacterial culture and Gram stain

Secondary Outcomes

  • Statistical association between risk factors and test results(up to 3 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials